Pharmaceuticals & Biopharmaceuticals

Toronto – October 07, 2026 -- Vector Science and Therapeutics Corp. (TSXV: PAIN) has made an investment in Scoreboard, Inc., a performance wellness company co-founded by NBA Hall of Famer Gary Payton, through a Simple Agreement for Future Equity.

Vector and Scoreboard will co-develop peptide-based products for athletic performance, recovery and longevity

The two companies plan to jointly develop products using peptides formulated and manufactured by Vector, which tests all materials for purity, potency, endotoxin levels and sterility through validated analytical methods.

Doylestown, Pa. – October 07, 2026 -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will present new patient data for its LACRIFILL Canalicular Gel at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, running October 9-12.

More than 2,200 U.S. practices now use LACRIFILL Canalicular Gel

The company reports that over 2,200 ophthalmology and optometry practices across the United States have adopted the gel for patients undergoing cataract or refractive surgery and for managing dry eye disease. More than 130,000 patients have been treated with the therapy to date.

Patient survey shows 96% report improved comfort after cataract surgery

In Nordic Pharma's latest patient experience survey, 96% of respondents who had cataract surgery within the past six months said LACRIFILL Canalicular Gel made their eyes feel better. Among all surveyed patients, 91% reported the same improvement.

LONDON – – October 07, 2026 -- OncoBayes has completed preclinical work on OB-001, an oral drug candidate designed to overcome antibody-drug conjugate (ADC) resistance and boost brain penetration of tyrosine kinase inhibitors (TKIs), the privately held clinical-stage pharmaceutical company announced.

OB-001 raises osimertinib brain exposure by nearly 400% in mouse studies

In perfused-brain mouse models, pretreatment with OB-001 increased brain exposure of osimertinib by almost 400%, while plasma exposure remained broadly unchanged. The data, presented at AACR 2026, covered four gold-standard kinase inhibitors and showed systemic drug levels were largely unaffected by the efflux-pump inhibition.

Milan – October 07, 2026 -- LG CNS is showcasing a pharma-specific manufacturing automation suite at CPHI Milan 2026, the world's largest pharmaceutical and biotech trade show, as the Korean AI transformation firm expands into drug-manufacturing technology. The company is the only Korean participant in CPHI's newly created "AI & Tech" zone this year, presenting its booth under the theme "Autonomous Factory in Pharma."

CPHI Milan draws 60,000 visitors and 3,000 exhibitors from 160 countries

The Milan event is CPHI's flagship show, held annually across global venues including the United States, Europe, Asia and the Middle East, and is considered the premier gathering for pharma and biotech manufacturing technology.

Tokyo – October 07, 2026 -- Astellas Pharma Inc. (TSE: 4503) will present 21 abstracts from its oncology portfolio at the European Society for Medical Oncology Congress 2026, running October 23-27 in Madrid, Spain.

Enfortumab vedotin combination shows longest follow-up data yet in urothelial cancer

Presentations on PADCEV (enfortumab vedotin) plus pembrolizumab include the longest follow-up reported to date for patients with locally advanced or metastatic urothelial cancer, alongside subgroup and treatment-setting analyses. Additional data cover trials in progress evaluating bladder preservation strategies in muscle-invasive bladder cancer.

Washington, D.C. – October 07, 2026 -- CNBC's Becky Quick will moderate a rare disease leadership dialogue featuring the CEOs of BioMarin, Jazz Pharmaceuticals and Otsuka North America Pharmaceutical alongside NORD CEO Pam Gavin, the National Organization for Rare Disorders announced.

Panel convenes three biopharma chiefs at NORD's Breakthrough Summit on October 26

The session, titled "Next Decade of Rare Disease: A CEO Leadership Dialogue," takes place at 11 a.m. ET on Monday, October 26, in Washington, D.C., during the three-day NORD Rare Diseases & Orphan Products Breakthrough Summit running October 25–27. Participants include Alexander Hardy, President and CEO of BioMarin; Renee Gala, President and CEO of Jazz Pharmaceuticals; Tarek Rabah, President and CEO of Otsuka North America Pharmaceutical; and NORD CEO Pam Gavin.

San Diego – – October 07, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has expanded its global collaboration and license agreement with argenx, adding two new exclusive targets for its ENHANZE drug-delivery platform and raising the partner's total exclusive target count from six to eight.

Halozyme adds two exclusive ENHANZE targets to argenx licensing deal

The expanded agreement builds on the companies' existing collaboration, which already delivered VYVGART Hytrulo, a subcutaneous treatment for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Under the new terms, Halozyme is eligible for milestone payments tied to development and regulatory progress on the additional targets, plus royalties on future net sales of any resulting products using ENHANZE.

Burlingame, Calif. – October 07, 2026 -- Enliven Therapeutics, Inc. (Nasdaq: ELVN) has reached alignment with the U.S. Food and Drug Administration on the final design of ENABLE-2, a pivotal Phase 3 trial testing relcobatinib against standard second-generation therapies in previously treated chronic myeloid leukemia (CML). The company remains on track to initiate the trial before year-end 2026.

FDA clears path for 450-patient head-to-head comparison

ENABLE-2 is designed to enroll approximately 450 adults with CML who have already received one or more tyrosine kinase inhibitors (TKIs). Participants will be randomized 1:1 to receive either relcobatinib at 80 mg once daily or an investigator-selected second-generation TKI -- dasatinib, nilotinib, or bosutinib. The primary endpoint is major molecular response (MMR) at Week 24, with MMR at Week 96 as a key secondary measure.

Altstätten, Switzerland and Boston – October 07, 2026 -- The Centers for Medicare & Medicaid Services has approved a New Technology Add-On Payment for icotec's CMORE® CT spine implant system, effective October 07, 2026, opening expanded reimbursement access for eligible hospitals treating Medicare patients.

CMS reimbursement decision follows April 2025 Break-Through Device Designation

icotec's CMORE® Cervicothoracic System received FDA Break-Through Device Designation in April 2025, a status that preceded the latest NTAP approval. The NTAP program provides eligible hospitals additional payment for qualifying technologies used in traditional Medicare procedures, applying here to specified spinal conditions and surgeries.

Boca Raton, Fla. – October 06, 2026 -- C5 Biomedical LLC CEO Tim Maye, CTBS, is being honored tonight in San Francisco as one of 50 individuals named to the Association for Advancing Tissue and Biologics' (AATB) one-time "50 at 50" list, marking the organization's 50th anniversary.

Maye's 28-year tissue banking career includes six years chairing AATB's Standards Committee

Maye has held his Certified Tissue Bank Specialist (CTBS) credential since 1999 and spent six years chairing AATB's Standards Committee, the body responsible for the tissue banking standards the industry operates under today. He founded C5 Biomedical in 2021 and remains on the Standards Committee.